Clene Inc (CLNN)
NASDAQ:CLNN
Want to see CLNN full AI Analyst Report?
Top Page
Clene
(NASDAQ:CLNN)
Select Model
Select Model
Rating:52Neutral
Price Target:
$5.50
▼(-12.84% Downside)
Action:Reiterated
Date:05/23/26
The score is held down primarily by weak financial fundamentals—minimal revenue, large ongoing losses, negative equity, and significant cash burn requiring continued financing. Offsetting factors include constructive technical trend signals and positive corporate developments (extended debt maturities, new equity funding, and encouraging FDA feedback supporting a potential accelerated-approval pathway), but these do not fully mitigate the current financial risk profile.
Positive Factors
Regulatory progress toward accelerated approval
FDA feedback that data may support an accelerated-approval NDA and that neurofilament light could serve as a surrogate endpoint materially shortens the regulatory path if substantiated. This creates a structural opportunity to reach patients faster and reduces time and cost to potential market entry versus full traditional approval.
Negative Factors
Negative equity and elevated leverage
Negative shareholders' equity combined with roughly $22M of debt signals persistent historical losses and weakened capital structure. This limits financial flexibility, raises creditor reliance, and increases the risk that future financing will be costly or dilutive, constraining strategic options over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress toward accelerated approval
FDA feedback that data may support an accelerated-approval NDA and that neurofilament light could serve as a surrogate endpoint materially shortens the regulatory path if substantiated. This creates a structural opportunity to reach patients faster and reduces time and cost to potential market entry versus full traditional approval.
Read all positive factors
Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$70.66M
Dividend YieldN/A
Average Volume (3M)944.13K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-61.71%
EPS Growth-11.47%
CountryUS
Employees75
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.25
Shares Outstanding12,778,307
10 Day Avg. Volume112,996
30 Day Avg. Volume944,130
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue624.83
Enterprise Value/Gross Profit-343.15
Enterprise Value/Ebitda-2.87
Forecast
1Y Price Target
$32.20Price Target Upside410.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$172.83K
Clene Business Overview & Revenue Model
Company Description
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagsh...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Clene has not consistently generated product sales from approved therapies; its ability to generate operating revenue is primarily tied to clinical development and financing activities. The company’s ...
Clene Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.00K | 200.00K | 342.00K | 654.00K | 473.00K | 723.00K |
| Gross Profit | -244.00K | 157.00K | 272.00K | 533.00K | 447.00K | 434.00K |
| EBITDA | -29.20M | -22.00M | -33.69M | -43.24M | -25.60M | -8.34M |
| Net Income | -33.51M | -26.17M | -39.40M | -49.50M | -29.92M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 21.66M | 18.13M | 27.34M | 52.34M | 44.49M | 63.06M |
| Cash, Cash Equivalents and Short-Term Investments | 5.94M | 5.19M | 12.15M | 35.00M | 23.32M | 50.29M |
| Total Debt | 22.05M | 21.67M | 20.84M | 32.16M | 31.82M | 24.04M |
| Total Liabilities | 40.47M | 35.72M | 36.19M | 38.95M | 41.26M | 50.47M |
| Stockholders Equity | -18.81M | -17.59M | -8.86M | 13.39M | 3.24M | 12.60M |
Cash Flow | ||||||
| Free Cash Flow | -18.10M | -18.59M | -21.34M | -30.50M | -44.19M | -35.96M |
| Operating Cash Flow | -18.06M | -18.55M | -21.33M | -30.17M | -39.01M | -34.62M |
| Investing Cash Flow | -39.00K | -39.00K | 6.32M | -1.50M | -10.16M | -1.33M |
| Financing Cash Flow | 14.08M | 11.52M | -1.53M | 42.16M | 17.25M | 27.11M |
Clene Technical Analysis
Neutral
6.31
Price Trends
6.33
Negative
5.67
Positive
6.55
Negative
Market Momentum
-0.25
Positive
45.72
Neutral
32.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Neutral. The current price of 6.31 is above the 20-day moving average (MA) of 6.20, below the 50-day MA of 6.33, and below the 200-day MA of 6.55, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 32.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLNN.
Clene Risk Analysis
Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clene Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
52 Neutral | $70.66M | -2.03 | 233.93% | ― | -61.71% | -11.47% | |
51 Neutral | $24.86M | -3.40 | -695.82% | ― | 7.13% | -8.85% | |
49 Neutral | $160.27M | -4.67 | -52.35% | ― | ― | 27.21% | |
48 Neutral | $16.96M | -0.01 | -68.21% | ― | ― | ― | |
44 Neutral | $219.13M | -2.81 | -194.74% | ― | 160.53% | 12.32% |
* Consumer Defensive Sector Average
CLNN
Clene
5.84
1.42
32.13%
DYAI
Dyadic International
0.68
-0.25
-26.67%
AKTX
Akari Therapeutics
13.40
-30.20
-69.27%
ESLA
Estrella Immunopharma
1.06
0.11
11.58%
ANTX
AN2 Therapeutics, Inc.
4.74
3.66
338.89%
CAMP
CAMP4 Therapeutics Corporation
4.19
2.74
188.97%
Clene Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Clene Extends Note Maturities and Expands Equity Plan
Positive
May 22, 2026
On May 18, 2026, Clene Inc. amended its August 13, 2025 senior secured convertible promissory notes with AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way, extending the maturity to the earlier of August 13, 2027 or a change...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Clene Extends Debt Maturities and Strengthens Cash Runway
Positive
May 14, 2026
On May 11, 2026, Clene Inc. amended its December 2024 senior secured convertible promissory notes with Kensington Clene 2024, 4Life Research and La Scala Investments, extending the maturity to the earlier of August 13, 2027 or a change in control ...
Business Operations and StrategyPrivate Placements and Financing
Clene Announces $7 Million Registered Direct Equity Offering
Positive
May 5, 2026
On May 5, 2026, Clene Inc. priced a $7 million underwritten registered direct offering of 1,000,000 shares of common stock at $7.00 per share to a single investor, with Canaccord Genuity acting as sole bookrunner and Maxim Group and D. Boral Capit...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Clene Advances CNM-Au8 Toward Accelerated ALS Approval
Positive
May 4, 2026
On May 4, 2026, Clene announced it had received final minutes from a Type C meeting in which the U.S. Food and Drug Administration said the company’s data may be capable of supporting an accelerated approval New Drug Application for CNM-Au8 ...
Business Operations and StrategyPrivate Placements and Financing
Clene Secures Third-Year NIH Subaward for ALS Program
Positive
Mar 17, 2026
On March 13, 2026, Clene entered into a third-year subaward agreement with New York University for up to $8.0 million under a previously announced four-year, $45.1 million National Institutes of Health grant supporting an Expanded Access Program f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.